ClinicalTrials.gg
RecruitingNCT07091630emnergizeUpdated Nov 16, 2026

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

A Phase 3 interventional study of Empasiprubart IV and Placebo IV in Chronic Inflammatory Demyelinating Polyneuropathy, CIDP and Chronic Inflammatory Demyelinating Polyradiculoneuropathy, sponsored by argenx. Recruiting at 95 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by argenx · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Nov 16, 2026First site in Colombia11 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States — 20 open to participants now, 25 under way, 10 of them phase 3. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States.

Planned enrollment
10th of 42
160 · median 74
Started
2025
with 12 others
Phase 3
15 of 55
8 open now
Primary completion
2027-10
later than 11 of 24 live
Registered
50th of 55
by date
Lead sponsor
7 of 55
argenx

Among the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States, this one is the 10th largest by planned enrollment of the 42 interventional ones that give a count, is one of 13 that started in 2025, is one of 15 in phase 3, reaches primary completion later than 11 of the 24 other live ones, and was the 50th registered.

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

137 studies on the registry are indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; 50 are open to participants now.

Browse Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies →

Open to participants now

20 of the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies recruiting now, 24 (67%) set no upper age limit and 9 (25%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months).

More information can be found here: https://clinicaltrials.argenx.com/emnergize

03

Conditions studied

  • Chronic Inflammatory Demyelinating Polyneuropathy
  • CIDP
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meets criteria for CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021)
  • Has either typical CIDP or 1 of the following CIDP variants: motor CIDP (including motor-predominant CIDP), multifocal CIDP (also known as Lewis-Sumner syndrome), focal CIDP, or distal CIDP
  • Has residual disability and active disease
  • Has not received previous treatment for CIDP; or has stopped receiving CIDP treatment; or is receiving CIDP treatment (pulsed or oral , immunoglobulins, PLEX, or FcRn inhibitors)
  • Participants already receiving CIDP treatment will have to discontinue their CIDP treatment before first IMP administration and must be willing to switch to the study IMP

Exclusion criteria

Exclusion Criteria:

  • Meets the criteria for possible CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021)
  • Sensory CIDP (including sensory-predominant CIDP)
  • Polyneuropathy of other causes
  • Clinical diagnosis of systemic lupus erythematosus (SLE)
  • Use of other long-acting immunomodulatory treatment or prior treatment (at any time) with total lymphoid irradiation or bone marrow transplantation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Part A - Empasiprubart

    Participants receive empasiprubart during part A

    Biological: Empasiprubart IV

  • Placebo comparator
    Part A - Placebo

    Participants receive placebo during part A

    Other: Placebo IV

  • Experimental
    Part B - Empasiprubart

    Participants receive empasiprubart during part B. Participants from the empasiprubart arm in part A will receive placebo once to maintain the blind of part A.

    Biological: Empasiprubart IV

Interventions

  • Intravenous infusion of empasiprubart

  • OtherPlacebo IV

    Intravenous infusion of placebo

06

What researchers measure

Primary outcomes

  1. Reduction of ≥1 point compared with baseline in aINCAT score at week 24

    The Adjusted Inflammatory Neuropathy Cause and Treatment Disability Score (aINCAT) score is a 10-point scale that covers the functionality of legs and arms. The score varies between 0 and 10 (higher score, worse outcome).

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Change from baseline in I-RODS centile points score

    Inflammatory Rasch-built Overall Disability Scale (I-RODS) assesses the limitations of activities and social participation in patients with inflammatory neuropathies like CIDP. The score ranges from 0 to 100 (higher score, worse outcome).

    Time frame: Up to 24 weeks (part A) + 96 weeks (Part B)

  2. Change from baseline in MRC-SS at week 24

    The Medical Research Council Sum Score evaluates motor strength. Evaluated on 6 muscle groups on each side, the score varies from 0 to 60 (lower score, worse outcome)

    Time frame: Up to 24 weeks

  3. Change from baseline in grip strength (3-day moving average) in the dominant hand at week 24

    Time frame: Up to 24 weeks

  4. Time to reduction of ≥1 point from baseline in aINCAT score

    The Adjusted Inflammatory Neuropathy Cause and Treatment Disability Score (aINCAT) score is a 10-point scale that covers the functionality of legs and arms. The score varies between 0 and 10 (higher score, worse outcome).

    Time frame: Up to 24 weeks

  5. Change from baseline in TUG

    The Timed Up and Go Test (TUG) is a simple test top assess a person's mobility in which the time expended to rise from a chair, walk 3 meters, turn around, walk back to the chair, and sit down is measured.

    Time frame: Up to 24 weeks (part A) + 96 weeks (Part B)

  6. Time to increase of ≥1 point compared with baseline in aINCAT score up to week 24

    The Adjusted Inflammatory Neuropathy Cause and Treatment Disability Score (aINCAT) score is a 10-point scale that covers the functionality of legs and arms. The score varies between 0 and 10 (higher score, worse outcome).

    Time frame: Up to 24 weeks

  7. Change from baseline in grip strength (3-day moving average) of both hands over time

    Time frame: Up to 24 weeks (part A)

  8. Change from baseline in grip strength (daily average) for both hands

    Time frame: Up to 96 weeks (Part B)

  9. Change from baseline in MRC-SS over time

    The Medical Research Council Sum Score evaluates motor strength. Evaluated on 6 muscle groups on each side, the score varies from 0 to 60 (lower score, worse outcome).

    Time frame: Up to 96 weeks (Part B)

  10. Change from baseline in aINCAT score over time

    The Adjusted Inflammatory Neuropathy Cause and Treatment Disability Score (aINCAT) score is a 10-point scale that covers the functionality of legs and arms. The score varies between 0 and 10 (higher score, worse outcome).

    Time frame: Up to 24 weeks + 96 weeks (Part B)

  11. Change from baseline in EQ-5D-5L over time

    EQ-5D-5L questionnaire is a patient-reported outcome measure, ranging 0 to 100 (lower score, worse outcome).

    Time frame: Up to 24 weeks (Part A) + 96 weeks (Part B)

  12. Change from baseline in RT-FSS over time

    Rasch-Transformed Fatigue Severity Scale (RT-FSS) is a patient-reported outcome measure to distinguish fatigue from clinical depression.

    Time frame: Up to 24 weeks (Part A) + 96 weeks (Part B)

  13. Change from baseline in BPI-SF over time

    The Brief Pain Inventory-Short Form (BPI-SF) is a patientreported outcome measure to assess pain severity and pain interference.

    Time frame: Up to 24 weeks (Part A) + 96 weeks (Part B)

  14. PGI-S values over time

    The Patient Global Impression of Severity (PGI-S) is a patient-reported outcome measure that reflects the patient's belief about the severity of the illness.

    Time frame: Up to 24 weeks (Part A) + 96 weeks (Part B)

  15. PGI-C values over time

    The Patient Global Impression of Change (PGI-C) is a patient-reported outcome measure that reflects the patient's belief about the efficacy of treatment.

    Time frame: Up to 24 weeks (Part A) + 96 weeks (Part B)

  16. Incidence of ADA against empasiprubart in serum

    Anti-drug antibodies

    Time frame: Up to 24 weeks + 96 weeks (Part B)

  17. Incidence of NAb against empasiprubart in serum

    Neutralizing antibodies

    Time frame: Up to 24 weeks + 96 weeks (Part B)

  18. Incidence of AEs and SAEs

    Time frame: Up to 24 weeks + 96 weeks (Part B)

  19. Percentage change from baseline in free C2 and total C2 over time

    Time frame: Up to 24 weeks (part A) + 96 weeks (Part B)

  20. Serum concentrations of empasiprubart over time

    Time frame: Up to 24 weeks (Part A) + 96 weeks (Part B)

  21. Reduction of ≥1 point in aINCAT over time

    The Adjusted Inflammatory Neuropathy Cause and Treatment Disability Score (aINCAT) score is a 10-point scale that covers the functionality of legs and arms. The score varies between 0 and 10 (higher score, worse outcome)

    Time frame: Up to 96 weeks (Part B)

  22. Increase of ≥1 point from baseline in aINCAT over time

    The Adjusted Inflammatory Neuropathy Cause and Treatment Disability Score (aINCAT) score is a 10-point scale that covers the functionality of legs and arms. The score varies between 0 and 10 (higher score, worse outcome).

    Time frame: Up to 96 weeks (Part B)

07

Study locations

95 of 95 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2025
First posted
Jul 29, 2025
StartActual
Sep 16, 2025
Primary completionEst.
Oct 7, 2027
CompletionEst.
Jan 23, 2031
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
11 sites added, 1 site removed — first site in Colombia
Show 11 added (3 Colombia, 3 China, 2 United States, 1 Brazil, 1 United Kingdom, 1 Italy)
  • Vero Beach Neurology and Research Institute · Vero Beach, United States
  • Escola Bahiana de Medicina e Saude Publica · Salvador, Brazil
  • Hospital Neurologico de Colombia Fundacion Ivan Jimenez - El Neurologico · Medellín, Colombia
  • Kent and Canterbury Hospital · Canterbury, United Kingdom
  • Banner University of Arizona Medical Center · Tucson, United States
  • Guangzhou First People's Hospital · Guanzhou, China
  • The First Affiliated Hospital of Soochow University · Suzhou, China
  • Oinsamed S.A.S La Clinica Misericordia Internacional · Barranquilla, Colombia
  • Hospital Alma Máter de Antioquia · Medellín, Colombia
  • Azienda Ospedaliera di Rilievo Nazionale (AORN) Antonio Cardarelli · Naples, Italy
  • The Second Affiliated Hospital of Nanchang University (Donghu Campus) · Nanchang, China
Show 1 removed
  • Institutul de Neurologie si Neurochirurgie · Chisinau, Moldova
across 3 updates, Oct 16, 2026 – Nov 16, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Regina Maria Brasov Hospital · Brasov, RomaniaContact •••3118→•••3118
  • Institutul de Neurologie si Neurochirurgie · Chisinau, MoldovaContact v•••@usmf.md · •••6641→o•••@mail.ru · •••3354
across 2 updates, Oct 27, 2026 – Nov 16, 2026
Show all 4 updates
  1. Nov 16, 2026
    1 site added
    Show site
    • The Second Affiliated Hospital of Nanchang University (Donghu Campus) · Nanchang, China
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Institutul de Neurologie si Neurochirurgie · Chisinau, MoldovaContact v•••@usmf.md · •••6641→o•••@mail.ru · •••3354
  2. Nov 9, 2026
    6 sites added, 1 site removed
    Show 6 added (2 China, 2 Colombia, 1 United States, 1 Italy)
    • Banner University of Arizona Medical Center · Tucson, United States
    • Guangzhou First People's Hospital · Guanzhou, China
    • The First Affiliated Hospital of Soochow University · Suzhou, China
    • Oinsamed S.A.S La Clinica Misericordia Internacional · Barranquilla, Colombia
    • Hospital Alma Máter de Antioquia · Medellín, Colombia
    • Azienda Ospedaliera di Rilievo Nazionale (AORN) Antonio Cardarelli · Naples, Italy
    Show 1 removed
    • Institutul de Neurologie si Neurochirurgie · Chisinau, Moldova
  3. Oct 27, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Regina Maria Brasov Hospital · Brasov, RomaniaContact •••3118→•••3118
  4. Oct 16, 2026
    4 sites added — first site in Colombia
    Show 4 added (1 United States, 1 Brazil, 1 Colombia, 1 United Kingdom)
    • Vero Beach Neurology and Research Institute · Vero Beach, United States
    • Escola Bahiana de Medicina e Saude Publica · Salvador, Brazil
    • Hospital Neurologico de Colombia Fundacion Ivan Jimenez - El Neurologico · Medellín, Colombia
    • Kent and Canterbury Hospital · Canterbury, United Kingdom

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07091630
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Jul 29, 2025
Start date
Sep 16, 2025
Primary completion
Oct 7, 2027 (estimated)
Completion
Jan 23, 2031 (estimated)
Last update
Nov 16, 2026

Study contacts

Sabine Coppieters, MD
Contact
clinicaltrials@argenx.com
857-350-4834

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empasiprubart

Start the discussion